Adragos Hub

Pharmaceutical and biotech companies selecting sterile injectable contract development and manufacturing organisation (CDMO) services in Europe must evaluate partners across seven critical dimensions: programme-fit and technical capability, regulatory standing and Good Manufacturing Practice (GMP) certifications, Chemistry, Manufacturing and Controls (CMC) […]

April 15, 2026 Adragos Pharma Kawagoe K.K. (Headquarters: Kawagoe, Saitama; Representative Director and President: Masanori Kurogome) has signed a basic agreement with Towa Pharmaceutical Co., Ltd. (Headquarters: Kadoma, Osaka; President and CEO: Itsuro Yoshida) to establish a strategic collaboration aimed […]

A Strategic Guide to Navigating Early-Stage Fill-Finish for Biologics Optimising early-stage fill-finish for biologics begins at a point where resources are constrained, knowledge is incomplete, and regulatory scrutiny is intense. The central task is to convert a promising molecule into […]

For pharma and biotech companies, selecting a sterile manufacturing partner is about more than equipment or capacity alone. It is about choosing a site that can combine reliable PFS manufacturing, sterile vial production, quality systems and operational support in a way that enables […]

Munich, April 1, 2026 – Adragos Pharma, a global contract development and manufacturing organization (CDMO), today announced that it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of Europe’s largest manufacturing facilities for sterile […]

Why small-molecule development risk is often discovered too late  Small-molecule development does not usually fail because teams lack effort. It fails because risk is discovered too late. The cost then appears as rework, delayed approvals, or supply plans that collapse […]